DC
Therapeutic Areas
Eternygen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SLC13A5 Inhibitor Program | Metabolic Diseases (NAFLD/NASH, CKD, Diabetes, Obesity) | Pre-clinical |
| SLC13A5 Modulator Program | Age-Related Bone Loss / Osteoporosis | Pre-clinical |
| Drug | Indication | Phase |
|---|---|---|
| SLC13A5 Inhibitor Program | Metabolic Diseases (NAFLD/NASH, CKD, Diabetes, Obesity) | Pre-clinical |
| SLC13A5 Modulator Program | Age-Related Bone Loss / Osteoporosis | Pre-clinical |